PAH market dynamics
Jun 17, 2024
WINREVAIR Approval for Pulmonary Arterial Hypertension Treatment: Is It A Game-Changer for Merck?
Merck’s investment of $11.5 billion in acquiring Acceleron Pharma is expected to yield significant returns with the FDA’s approval of WINREVAIR (sotatercept), a pivotal component of the acquisition, for the treatment of pulmonary arterial hypertension. An estimated prevalence of pulmonary hypertension at the pop...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
